NeuroSense Provides Update on Nasdaq Listing Compliance
PR Newswire•02/10/2026•16:15 ET
0
Key Highlights
- ➤NeuroSense (NRSN) failed to regain Nasdaq’s $35 million minimum market value requirement.
- ➤NeuroSense (NRSN) intends to appeal and seek up to 180 additional days for compliance.
- ➤Timely hearing request stays suspension and SEC Form 25-NSE filing pending a Panel decision.
- ➤NeuroSense (NRSN) regained $1.00 minimum bid-price compliance after a 1-for-20 reverse split.
- ➤NRSN and NRSNW are expected to continue trading during the Nasdaq hearing process.
Expert Statements
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“Regaining compliance with the minimum bid price requirement is an important step, and we intend to present the Hearings Panel with our plan to meet Nasdaq's remaining continued listing requirement.”
Alon Ben-Noon, Chief Executive Officer of NeuroSense
“In parallel, we remain focused on advancing PrimeC in ALS, including preparations for our Phase 3 PARAGON trial and our planned New Drug Submission to Health Canada, as well as other milestones and strategic steps we are evaluating, in order to bring value to our shareholders.”
NeuroSense Provides Update on Nasdaq Listing Compliance PR Newswire
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement
Get started
Create a free account to read the full story.